{"id":32907,"date":"2025-07-30T08:47:48","date_gmt":"2025-07-30T08:47:48","guid":{"rendered":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/"},"modified":"2025-07-30T08:47:48","modified_gmt":"2025-07-30T08:47:48","slug":"estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/","title":{"rendered":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III"},"content":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; MERCK KGAA<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; MERCK KGAA<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-32907","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; MERCK KGAA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:47:48+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III\",\"datePublished\":\"2025-07-30T08:47:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/\"},\"wordCount\":55,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/\",\"name\":\"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:47:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima","og_description":"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; II &#8211; MERCK KGAA","og_url":"https:\/\/ibima.eu\/es\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:47:48+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III","datePublished":"2025-07-30T08:47:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/"},"wordCount":55,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/","url":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/","name":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:47:48+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-multicentrico-doble-ciego-aleatorizado-y-controlado-de-m7824-con-quimiorradioterapia-concurrente-seguida-de-m7824-en-comparacion-con-quimiorradioterapia-concurrente-mas-placebo-seguida-de-du\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio multic\u00e9ntrico, doble ciego, aleatorizado y controlado de M7824 con quimiorradioterapia concurrente seguida de M7824 en comparaci\u00f3n con quimiorradioterapia concurrente m\u00e1s placebo seguida de durvalumab en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico irresecable en estadio III"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32907"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32907\/revisions"}],"predecessor-version":[{"id":55995,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32907\/revisions\/55995"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}